Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People with Type 2 Diabetes and Inadequate Glycaemic Control with Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial
absolute values given in Supplementary Fig
Common Side Effects The most common adverse events reported in clinical trials include: Nausea: Reported by approximately 40% of participants, typically mild to moderate, related to melanocortin receptor activation in brainstem areas Flushing: Facial redness occurring in about 20% of users Injection site reactions: Pain, erythema, or bruising common with subcutaneous administration Headache: Affecting approximately 11% of participants These events are generally transient, occurring soon after administration and resolving within hours without intervention
It makes those healthy choices far easier to keep by quieting constant hunger and cravings
What is the primary driver in the GLP-1 Aftercare & Metabolic Continuity Services Market
(2022, June 1)
